You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

monoclonal anti-CTLA-4 immunotherapy

Showing 1 - 25 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Pleural Biphasic Mesothelioma, Pleural Sarcomatoid Mesothelioma Trial (Nivolumab, Ipilimumab, Surgical Procedure)

Not yet recruiting
  • Pleural Biphasic Mesothelioma
  • Pleural Sarcomatoid Mesothelioma
  • Nivolumab
  • +5 more
  • (no location specified)
Dec 9, 2022

Recurrent Lung Non-Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8, Stage IVA Lung Cancer AJCC v8 Trial in Houston

Recruiting
  • Recurrent Lung Non-Small Cell Carcinoma
  • +3 more
  • Durvalumab
  • +2 more
  • Houston, Texas
    M D Anderson Cancer Center
Oct 10, 2022

Metastatic Nasopharyngeal Carcinoma, Recurrent Nasopharyngeal Carcinoma, Stage IV Nasopharyngeal Carcinoma AJCC v8 Trial

Not yet recruiting
  • Metastatic Nasopharyngeal Carcinoma
  • +2 more
  • Biospecimen Collection
  • +5 more
  • (no location specified)
Jun 13, 2023

Metastatic Malignant Tumor in the Liver, Metastatic Uveal Melanoma Trial in Houston (Aldesleukin, Autologous CD8+

Active, not recruiting
  • Metastatic Malignant Neoplasm in the Liver
  • Metastatic Uveal Melanoma
  • Aldesleukin
  • +3 more
  • Houston, Texas
    M D Anderson Cancer Center
Jan 20, 2023

Advanced Malignant Solid Tumor, C-KIT Tyrosine Kinase Protein Overexpression, Clinical Stage IV Cutaneous Melanoma AJCC v8 Trial

Recruiting
  • Advanced Malignant Solid Neoplasm
  • +8 more
  • Imatinib Mesylate
  • Ipilimumab
  • Houston, Texas
    M D Anderson Cancer Center
Aug 1, 2022

Advanced Malignant Solid Tumor, Metastatic Malignant Tumor in the Liver, Metastatic Malignant Tumor in the Lung Trial in Houston

Not yet recruiting
  • Advanced Malignant Solid Neoplasm
  • +3 more
  • Hafnium Oxide-containing Nanoparticles NBTXR3
  • +3 more
  • Houston, Texas
    M D Anderson Cancer Center
Feb 2, 2022

Metastatic Melanoma, Stage IV Cutaneous Melanoma AJCC v6 and v7 Trial in Houston (biological, drug, other)

Active, not recruiting
  • Metastatic Melanoma
  • Stage IV Cutaneous Melanoma AJCC v6 and v7
  • Aldesleukin
  • +4 more
  • Houston, Texas
    M D Anderson Cancer Center
Feb 2, 2022

Advanced Malignant Solid Tumor, Metastatic Malignant Solid Tumor, Refractory Malignant Solid Tumor Trial in Canada, United

Recruiting
  • Advanced Malignant Solid Neoplasm
  • +2 more
  • Biopsy
  • +6 more
  • Boston, Massachusetts
  • +5 more
Jan 7, 2023

Advanced Cancer Trial in Worldwide (Relatlimab, Nivolumab, BMS-986205)

Recruiting
  • Advanced Cancer
  • Relatlimab
  • +3 more
  • Duarte, California
  • +23 more
Oct 24, 2022

Constitutional Mismatch Repair Deficiency Syndrome, Hematopoietic and Lymphoid Cell Tumor, Lynch Syndrome Trial in Canada,

Withdrawn
  • Constitutional Mismatch Repair Deficiency Syndrome
  • +11 more
  • Biospecimen Collection
  • +2 more
  • Palo Alto, California
  • +8 more
Sep 9, 2022

Cervical Cancer Trial in Amsterdam (Anti-PD-1 antibody balstilimab)

Not yet recruiting
  • Cervical Cancer
  • Anti-PD-1 antibody balstilimab
  • Amsterdam, Netherlands
    Amsterdam UMC
Oct 17, 2023

Metastatic Renal Cell Carcinoma, Stage III Renal Cell Cancer AJCC v8, Stage IV Renal Cell Cancer AJCC v8 Trial in United States

Recruiting
  • Metastatic Renal Cell Carcinoma
  • +3 more
  • Avelumab
  • +7 more
  • Danville, Illinois
  • +4 more
Jul 29, 2022

Colon Carcinoma Metastatic in the Liver, Colorectal Adenocarcinoma, Pancreatic Adenocarcinoma Trial in Atlanta, Rochester

Active, not recruiting
  • Colon Carcinoma Metastatic in the Liver
  • +13 more
  • Anti-SEMA4D Monoclonal Antibody VX15/2503
  • +3 more
  • Atlanta, Georgia
  • +3 more
Dec 15, 2021

Advanced Cancer, Angiosarcoma, Colorectal Cancer Without Liver Metastases Trial in United States (Botensilimab, Balstilimab)

Recruiting
  • Advanced Cancer
  • +7 more
  • Scottsdale, Arizona
  • +14 more
Sep 15, 2022

Lung Adenocarcinoma, Lung Non-Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8 Trial in United States (biological, procedure,

Recruiting
  • Lung Adenocarcinoma
  • +2 more
  • Ipilimumab
  • +5 more
  • Conroe, Texas
  • +4 more
May 25, 2022

Skin Health and Quality of Life in Patients Receiving

Not yet recruiting
  • Lung Cancer
  • +7 more
  • EQ-5D-5L questionnaire
  • +2 more
  • Roma, Italy
    Roberto Iacovelli
May 17, 2023

Clinical Stage III Cutaneous Melanoma AJCC v8, Clinical Stage III Merkel Cell Carcinoma AJCC v8, Clinical Stage IV Cutaneous

Not yet recruiting
  • Clinical Stage III Cutaneous Melanoma AJCC v8
  • +12 more
  • Biopsy
  • +8 more
  • (no location specified)
Jun 8, 2023

Glioblastoma, Malignant Glioma, Recurrent Glioblastoma Trial in Worldwide (biological, drug, other)

Recruiting
  • Glioblastoma
  • +5 more
  • Ipilimumab
  • +4 more
  • Birmingham, Alabama
  • +19 more
Aug 16, 2022

Clinical Stage I HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC (American Joint Committee on Cancer) v8, Clinical

Active, not recruiting
  • Clinical Stage I HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC (American Joint Committee on Cancer) v8
  • +8 more
  • Durvalumab
  • +6 more
  • Los Angeles, California
    UCLA / Jonsson Comprehensive Cancer Center
Dec 7, 2021

Metastatic Carcinoma in the Liver, Resectable Mass, Stage IV Colorectal Cancer AJCC v7 Trial in Houston (biological, other,

Completed
  • Metastatic Carcinoma in the Liver
  • +4 more
  • Durvalumab
  • +3 more
  • Houston, Texas
    M D Anderson Cancer Center
Jan 30, 2023

Synovial Sarcoma Trial in New York (ipilimumab)

Terminated
Has Results
  • Synovial Sarcoma
  • ipilimumab
  • New York, New York
    Memorial Sloan-Kettering Cancer Center
Jun 23, 2021

Fallopian Tube Endometrioid Tumor, Fallopian Tube High Grade Serous Adenocarcinoma, Malignant Ovarian Endometrioid Tumor Trial

Active, not recruiting
  • Fallopian Tube Endometrioid Tumor
  • +13 more
  • Orange, California
  • +19 more
Jan 10, 2023

Clear Cell Renal Cell Carcinoma?Resistance to Immunotherapy Trial in Shanghai (AK104(anti-PD-1/CTLA-4 bi-specific antibody

Recruiting
  • Clear Cell Renal Cell Carcinoma、Resistance to Immunotherapy
  • AK104（anti-PD-1/CTLA-4 bi-specific antibody ，intravenously）,lenvatinib（ targeted VEGFR 1-3、FGFR、PDGFRα， small molecule TKI，orally
  • Shanghai, Shanghai, China
    Shanghai Renji Hospital
Sep 12, 2023

Hepatocellular Carcinoma Trial in Beijing (AK104, Lenvatinib)

Recruiting
  • Hepatocellular Carcinoma
  • Beijing, Beijing, China
    Chinese PLA General Hospital
Oct 17, 2022

Melanoma, Non Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma Trial in Australia (AI-061)

Not yet recruiting
  • Melanoma
  • +16 more
  • Darlinghurst, New South Wales, Australia
  • +3 more
May 12, 2023